Ceftolozane/Tazobactam (Zerbaxa)

Ceftolozane/Tazobactam (Zerbaxa)


$143.68/Dose $2155.20/5 Days


General Information

Ceftolozane/tazobactam offers broad spectrum of activity against difficult-to-treat gram-negative bacteria such as ESBL-producing Enterobacteriaceae and drug-resistant P. aeruginosa.

  • Complicated Intra-abdominal Infections (in combination with metronidazole)
  • Complicated Urinary Tract Infections, including Pyelonephritis
  • Pneumonia (HAP, VAP)
  • Renal function
  • GI intolerance
  • C. difficile colitis
  • Immunologic: Hypersensitivity reaction, Anaphylaxis
  • Fever
  • Renal impairment
  • CNS: Headache
  • No significant drug interactions anticipated with substrates, inhibitors or inducers of cytochrome P450.
  • Tazobactam is a substrate for OAT1 and OAT2.
    • Co-administration with drugs that inhibit OAT1 or OAT3 may increase tazobactam concentrations.
  • Sodium Picosulfate - Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.
    • Consider using an alternative product for bowel cleansing prior to colonoscopy.
  • Warfarin - anticoagulation effect may be enhanced.

Zerbaxa restricted to Infectious Diseases (ID)/Antimicrobial Stewardship Program (ASP).

Antimicrobial class: Cephalosporin and Beta-lactamase Inhibitor

Pregnancy category: B

Average serum half life: Ceftolozane: ~3 to 4 hours; Tazobactam: ~2 to 3 hours